| 000 | 01254 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250518005942.0 | ||
| 264 | 0 | _c20190912 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a2000-1967 | ||
| 024 | 7 |
_a10.1080/03009734.2018.1516706 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHeld, Claes | |
| 245 | 0 | 0 |
_aWhen do we need clinical endpoint adjudication in clinical trials? _h[electronic resource] |
| 260 |
_bUpsala journal of medical sciences _cJan 2019 |
||
| 300 |
_a42-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aArtificial Intelligence |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xeconomics |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug and Narcotic Control |
| 650 | 0 | 4 | _aEndpoint Determination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMyocardial Infarction _xtherapy |
| 650 | 0 | 4 | _aOutcome Assessment, Health Care |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aSweden _xepidemiology |
| 773 | 0 |
_tUpsala journal of medical sciences _gvol. 124 _gno. 1 _gp. 42-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/03009734.2018.1516706 _zAvailable from publisher's website |
| 999 |
_c29042648 _d29042648 |
||